메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Pulsecare Medical Announces NMPA Approval of NxPFA™, the…

SHENZHEN, China, Aug. 4, 2025 -- Pulsecare Medical, a pioneer in cardiovascular intervention technologies, announced that its innovative NxPFA™ nanosecond pulsed field ablation (ns-PFA) systemhas received marketing approval from China's National Medical Products Administration (NMPA). As the world's first third-generation ns-PFA system utilizing high-voltage nanosecond pulses for pulmonary vein isolation (PVI) in atrial fibrillation (AF) treatment, this breakthrough marks the dawn of the PFA 3.0 era and represents the innovative capabilities of Pulsecare Medical in cardiovascular multimodal t
- 김갑성 기자
- 2025-08-04 21:30
Minaris Advanced Therapies Opens New State-of-the-Art GMP…

MUNICH, Aug. 4, 2025 -- Minaris Advanced Therapies, a leading global contract development and manufacturing organization and testing provider, has announced the opening of its new GMP manufacturing facility in Munich, Germany. The facility, located in Taufkirchen, strengthens Minaris' global manufacturing network and reinforces its position as a trusted partner in advancing cutting-edge therapies from concept to commercialization. Minaris' new facility builds on over 10 years of experience in both the clinical and commercial manufacture of advanced therapies.
- 김갑성 기자
- 2025-08-04 21:00
미나리스 어드밴스드 테라피스, 글로벌 세포•유전자 치료제 시장 성장 지원 위해 최신 GM…

뮌헨, 2025년 8월 4일 -- 세계적인 세포•유전자 치료제 위탁개발생산(CDMO) 조직이자 테스트 제공업체인 미나리스 어드밴스드 테라피스(Minaris Advanced Therapies)가 독일 타우프키르헨에 새로운 의약품 제조•품질관리 기준(GMP) 제조 시설을 개소했다고 밝혔다. 타우프키르헨 시설은 미나리스의 글로벌 제조 네트워크를 강화하고, 개념 단계부터 상용화까지 혁신적인 치료법을 개발하는 신뢰할 수 있는 파트너로서 회사의 위상을 공고히 할 것으로 기대된다. 세계 최고 수준의 인프라와 유연한 운영 체계를 갖춘 미나리스 신규 시설은 유럽에서 점점 더 커지고 있는 첨단 치료제 수요를 충족시키기 위해 건설됐다. 이 시설은 인근에 있는 기존 미나리스 팀의 주도로 운영되므로, 임상 및 상업용 제조뿐만 아니라 공정 및 분석 개발 분야에서 풍부한 경험을 갖추게 된다. 신규 시설은 뮌헨 국제공항(Munich International Airport)에서 불과 몇 분 거리에 위치해 있어 유럽을 비롯한 전 세계 고객에게 물류 면에서 전략적인 이점을 제공한다. 시설에는 다음과 같은 설비가 마련되어 있다.
- 김갑성 기자
- 2025-08-04 21:00
AXA Launches "AXA Health Concierge" Delivering a One-Stop H…

[ 메디채널 김갑성 기자 ] First-ever cross-border Green Medical Pass Integrating resources from both regions for efficient access to healthcare services HONG KONG, Aug. 4, 2025 -- AXA Hong Kong and Macau ("AXA") today announced the launch of its new "AXA Health Concierge" service, providing eligible customers[1] with a comprehensive, one-stop health management solution across Hong Kong and Mainland China. This initiative introduces the pioneering cross-border "Green Medical Pass,"[2], [3] offering priority access to medical appointments through a network o
- 김갑성 기자
- 2025-08-04 16:41
Breaking Through Core CT Technology Barriers!

[ 메디채널 김갑성 기자 ] World-Class Innovations to Debut at 2025 Medtec in September SHANGHAI, Aug. 4, 2025 -- A quiet revolution is underway in the field of high-end medical equipment, led by China's growing innovation power. Core CT technologies, once dominated by international giants, are now being steadily unlocked by Chinese companies, breaking through long-standing technical barriers. As a key showcase of this industrial transformation, the 2025 Medtec International Medical Device Design & Manufacturing Technology Exhibition will take place from September 24 to 26 at Halls 1 &
- 김갑성 기자
- 2025-08-04 16:40
HKBU leads the development of multifunctional nanorobots…

HONG KONG, Aug. 4, 2025 -- A collaborative research team led by Hong Kong Baptist University (HKBU) has developed a multifunctional nanorobot equipped with silver and gold nanorods to facilitate high-performance pollutant degradation and bacteria elimination, with its mobility navigated by the application of magnetic fields. The invention holds potential for broad applications in antibacterial treatments, sewage management, and biomedicine. Chemical pollution, pathogenic bacteria, and biofilms (a community of microorganisms embedded in a slimy matrix) pose significant threats t
- 김갑성 기자
- 2025-08-04 15:02
NX Taiwan Awarded Healthy Workplace Certification by "Ministry…

[ 메디채널 김갑성 기자 ] - Received High Praise for Promoting Health Management and Contributing to Local Communities - TOKYO, Aug. 4, 2025 -- Nippon Express (Taiwan) Co., Ltd. (hereinafter "NX Taiwan"), a group company of NIPPON EXPRESS HOLDINGS, INC., has been accorded Healthy Workplace Certification by the Health Promotion Administration (HPA) of "Taiwan's Ministry of Health and Welfare" in recognition of the company's commitment to creating sustainable workplaces that emphasize the health and welfare of employees. Logo: https://drive.google.com/file/d/1dqm0cxpYa
- 김갑성 기자
- 2025-08-04 15:00
Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial o…

TAIPEI, Aug. 4, 2025 -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation of a Phase 1/2 clinical trial in combination with tislelizumab and bevacizumab for patients with metastatic colorectal cancer (mCRC). This open-label, multi-center international study plans to enroll 66 patients with proficient mismatch repair (pMMR) or non-microsatellite instability-high (non-MSI-H) mCRC to evaluate the safety and preliminary efficacy of the triplet therapy. Enroll
- 김갑성 기자
- 2025-08-04 14:37
Raytone Biotech Announces First Patient Dosed in Clinical T…

BEIJING, Aug. 3, 2025 -- Raytone Biotech, a clinical-stage biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of RTP-008 during Q2 2025. RTP-008 is a bioabsorbable tacrolimus lacrimal canaliculus plug for the treatment of dry eye disease (DED). The milestone was achieved at Beijing Tongren Hospital, Capital Medical University, a leading ophthalmic research institution in China. The trial was conducted by Professor Ying Jie, Director of the Ophthalmology Center,
- 김갑성 기자
- 2025-08-04 14:29
Raytone Biotech Announces First Patient Dosed in Clinical T…

BEIJING, Aug. 4, 2025 -- Raytone Biotech, a biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of RTP-008 during Q2 2025. RTP-008 is a bioabsorbable tacrolimus lacrimal canaliculus plug for the treatment of dry eye disease (DED). The milestone was achieved at Beijing Tongren Hospital, Capital Medical University, a leading ophthalmic research institution in China. Unmet Needs in DED Management Dry eye is a multifactorial ocular surface disease. Management of DED is oft
- 김갑성 기자
- 2025-08-04 14:05

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 01시 40분